Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 29.75 | 30.31 | 17.24 | 23.96 | 17.20 | 29.64 | 345.63 | 34.13 | 23.23 | 54.63 | 82.10 | 22.88 | 34.30 | 24.82 | — | 33.93 | 38.48 | — | 167.41 | — | 104.25 |
| — | +2.3% | -95.0% | -29.8% | -25.9% | -45.7% | +321.0% | +49.2% | -32.3% | +120.1% | — | -32.6% | -10.9% | — | — | — | -63.1% | — | +127.2% | — | — | |
| P/S Ratio | 4.88 | 4.58 | 4.18 | 4.51 | 4.53 | 4.62 | 4.95 | 5.59 | 4.83 | 6.06 | 6.93 | 6.54 | 5.70 | 5.22 | 5.84 | 7.31 | 6.78 | 6.16 | 7.36 | 6.48 | 7.91 |
| — | -0.8% | -15.5% | -19.3% | -6.3% | -23.8% | -28.6% | -14.5% | -15.3% | +16.1% | +18.6% | -10.5% | -15.9% | -15.3% | -20.6% | +12.8% | -14.4% | -25.1% | -27.0% | -31.1% | -8.8% | |
| P/B Ratio | 4.38 | 4.40 | 4.00 | 4.47 | 4.79 | 4.71 | 4.47 | 5.42 | 4.42 | 5.70 | 5.99 | 6.04 | 5.68 | 5.10 | 5.83 | 7.05 | 6.81 | 6.55 | 6.58 | 5.88 | 6.96 |
| — | -6.6% | -10.6% | -17.6% | +8.4% | -17.3% | -25.3% | -10.2% | -22.2% | +11.8% | +2.6% | -14.3% | -16.5% | -22.1% | -11.3% | +19.8% | -2.2% | -11.9% | -17.0% | -28.9% | -37.6% | |
| P/FCF | 18.66 | 34.14 | 24.91 | 9.30 | 16.79 | 35.46 | 52.39 | 14.93 | 20.04 | 67.47 | 29.99 | 28.53 | 13.91 | 13.67 | — | 21.32 | 26.16 | 18.02 | — | — | 41.76 |
| — | -3.7% | -52.4% | -37.7% | -16.2% | -47.4% | +74.7% | -47.7% | +44.1% | +393.6% | — | +33.9% | -46.8% | -24.1% | — | — | -37.4% | -25.0% | — | — | — | |
| EV / EBITDA | 21.06 | 29.64 | 17.80 | 16.30 | 15.16 | 21.04 | 92.87 | 23.92 | 15.66 | 23.61 | 34.13 | 21.89 | 19.35 | 30.38 | — | 27.92 | 28.78 | 40.21 | 365.63 | — | 50.19 |
| — | +40.9% | -80.8% | -31.9% | -3.2% | -10.9% | +172.1% | +9.3% | -19.1% | -22.3% | — | -21.6% | -32.8% | -24.4% | — | — | -42.7% | +9.8% | +416.5% | — | — | |
| EV / EBIT | 22.08 | — | 13.94 | 15.62 | 12.81 | 20.17 | 122.26 | 20.43 | 16.13 | 24.38 | 34.20 | 17.13 | 20.10 | 19.67 | — | 25.29 | 26.66 | — | 97.50 | — | 63.99 |
| — | — | -88.6% | -23.5% | -20.5% | -17.2% | +257.5% | +19.3% | -19.8% | +24.0% | — | -32.3% | -24.6% | — | — | — | -58.3% | — | +36.1% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.2% | 97.6% | 98.3% | 97.8% | 98.2% | 98.4% | 98.4% | 98.5% | 98.7% | 98.4% | 98.5% | 98.4% | 97.8% | 97.5% | 98.0% | 98.1% | 98.4% | 98.7% | 98.5% | 98.7% | 98.6% |
| — | -0.8% | -0.1% | -0.7% | -0.5% | -0.1% | -0.2% | +0.2% | +1.0% | +1.0% | +0.6% | +0.2% | -0.7% | -1.3% | -0.5% | -0.6% | -0.2% | -0.2% | -0.3% | -0.1% | -0.4% | |
| Operating Margin | 21.6% | 15.8% | 22.8% | 26.2% | 30.1% | 21.2% | 4.1% | 22.6% | 29.5% | 24.6% | 19.3% | 29.2% | 28.3% | 16.3% | -27.2% | 25.1% | 22.6% | 14.5% | 1.0% | -11.6% | 15.0% |
| — | -25.4% | +454.1% | +15.7% | +1.8% | -14.0% | -78.6% | -22.5% | +4.4% | +51.5% | +170.9% | +16.2% | +25.1% | +12.4% | -2821.6% | +315.7% | +50.6% | -33.5% | -92.5% | -140.2% | +187.7% | |
| Net Margin | 16.7% | 15.1% | 24.3% | 19.1% | 26.4% | 15.6% | 1.4% | 16.4% | 20.9% | 11.0% | 8.4% | 28.7% | 16.7% | 21.1% | -18.2% | 21.6% | 17.7% | -4.5% | 4.5% | -2.3% | 7.6% |
| — | -3.7% | +1661.0% | +16.2% | +26.3% | +42.0% | -83.6% | -42.7% | +25.2% | -47.8% | +146.2% | +32.7% | -5.7% | +572.1% | -507.1% | +1023.3% | +132.3% | -130.5% | -67.0% | -101.7% | +134.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.4% | 3.9% | 5.9% | 4.9% | 7.4% | 4.1% | 0.3% | 3.9% | 5.0% | 2.7% | 1.9% | 7.0% | 4.3% | 5.4% | -4.5% | 5.5% | 4.6% | -1.2% | 1.0% | -0.5% | 1.7% |
| — | -5.0% | +1827.5% | +26.5% | +48.1% | +54.8% | -83.6% | -44.3% | +15.2% | -50.8% | +141.6% | +27.5% | -6.6% | +549.6% | -549.2% | +1119.5% | +169.3% | -135.3% | -63.5% | -101.5% | +124.3% | |
| ROA | 11.5% | 2.8% | 4.1% | 3.5% | 5.1% | 2.8% | 0.2% | 2.8% | 3.8% | 1.9% | 1.3% | 4.8% | 3.0% | 3.8% | -3.2% | 3.9% | 3.3% | -0.8% | 0.7% | -0.4% | 1.1% |
| — | -0.8% | +1845.5% | +21.5% | +35.4% | +47.9% | -83.5% | -41.3% | +24.7% | -50.1% | +139.8% | +22.8% | -7.8% | +571.6% | -591.5% | +1205.0% | +191.6% | -136.6% | -63.2% | -101.7% | +129.7% | |
| ROIC | 16.1% | 2.9% | 4.3% | 4.8% | 5.6% | 3.9% | 0.6% | 3.9% | 5.3% | 4.3% | 3.0% | 5.1% | 5.4% | 2.9% | -4.8% | 4.7% | 4.2% | 2.6% | 0.2% | -1.8% | 2.4% |
| — | -25.8% | +578.9% | +23.6% | +5.9% | -9.3% | -79.2% | -23.6% | -2.0% | +46.8% | +162.8% | +9.4% | +27.3% | +10.5% | -3292.8% | +353.8% | +77.8% | -26.8% | -91.6% | -138.4% | +164.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.10 | 0.12 | 0.13 | 0.30 | 0.16 | 0.18 | 0.18 | 0.09 | 0.10 | 0.21 | 0.19 | 0.14 | 0.15 | 0.15 | 0.15 | 0.17 | 0.19 | 0.35 | 0.32 | 0.32 |
| — | -38.2% | -32.5% | -27.4% | +227.0% | +59.6% | -17.7% | -8.4% | -32.3% | -31.6% | +39.0% | +24.7% | -20.6% | -20.9% | -55.3% | -52.0% | -47.0% | -44.5% | -3.1% | -12.4% | -48.6% | |
| Debt / EBITDA | 0.64 | 2.65 | 2.10 | 1.90 | 3.68 | 2.87 | 14.34 | 3.05 | 1.32 | 1.68 | 4.85 | 2.75 | 1.87 | 3.51 | — | 2.44 | 2.90 | 4.58 | 75.03 | — | 9.24 |
| — | -7.6% | -85.3% | -37.7% | +178.6% | +71.2% | +195.6% | +11.1% | -29.2% | -52.2% | — | +12.6% | -35.6% | -23.4% | — | — | -68.7% | -31.1% | +494.0% | — | — | |
| Current Ratio | 3.39 | 1.87 | 2.93 | 3.39 | 3.38 | 3.20 | 3.13 | 3.40 | 4.37 | 4.19 | 2.52 | 2.45 | 2.39 | 2.57 | 3.83 | 2.70 | 2.49 | 3.57 | 4.02 | 3.96 | 4.45 |
| — | -41.5% | -6.5% | -0.1% | -22.5% | -23.6% | +24.1% | +38.4% | +83.1% | +63.1% | -34.1% | -9.2% | -4.0% | -28.0% | -4.6% | -31.7% | -44.2% | -31.6% | -29.7% | -27.4% | +135.1% | |
| Quick Ratio | 3.30 | 1.75 | 2.85 | 3.30 | 3.27 | 3.10 | 3.02 | 3.28 | 4.26 | 4.08 | 2.47 | 2.40 | 2.34 | 2.51 | 3.74 | 2.64 | 2.41 | 3.47 | 3.90 | 3.83 | 4.34 |
| — | -43.4% | -5.6% | +0.5% | -23.1% | -24.2% | +22.2% | +37.1% | +81.8% | +62.4% | -33.9% | -9.2% | -2.7% | -27.4% | -4.1% | -31.2% | -44.5% | -31.8% | -29.7% | -27.6% | +133.3% | |
| Interest Coverage | — | 52.24 | — | — | — | — | — | — | — | 2.98 | 95.73 | 181.18 | 128.36 | 93.54 | -92.91 | 108.18 | 82.58 | -9.59 | 9.23 | -1.09 | 5.62 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBIX stock.
Neurocrine Biosciences, Inc.'s current P/E is 29.8x. The average P/E over the last 4 quarters is 22.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Neurocrine Biosciences, Inc.'s current operating margin is 21.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Neurocrine Biosciences, Inc.'s business trajectory between earnings reports.